{"id":748989,"date":"2026-04-24T03:57:14","date_gmt":"2026-04-24T03:57:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/748989\/"},"modified":"2026-04-24T03:57:14","modified_gmt":"2026-04-24T03:57:14","slug":"dopamine-depletion-the-hidden-driver-of-alzheimers-memory-loss","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/748989\/","title":{"rendered":"Dopamine Depletion: The Hidden Driver of Alzheimer\u2019s Memory Loss"},"content":{"rendered":"<p><strong>Summary: <\/strong>For decades, Alzheimer\u2019s research has focused almost exclusively on toxic proteins like amyloid-beta and tau. However, a new study has identified a new culprit: dopamine dysfunction in the entorhinal cortex.<\/p>\n<p>Researchers discovered that dopamine levels in this critical \u201cmemory gateway\u201d drop to less than one-fifth of normal levels in Alzheimer\u2019s models, preventing neurons from encoding new experiences. Most significantly, the study proved that memory could be restored using Levodopa, a common drug already FDA-approved for Parkinson\u2019s disease.<\/p>\n<p><strong>Key Facts<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li><strong>The Dopamine Drop:<\/strong> Dopamine levels in the entorhinal cortex were found to be reduced by over <strong>80%<\/strong>, leaving neurons unable to respond to stimuli or form associative memories.<\/li>\n<li><strong>Restoring Memory:<\/strong> Using both light-based (optogenetic) tools and the drug <strong>Levodopa<\/strong>, researchers successfully \u201crescued\u201d memory function in mice, allowing them to learn and remember again.<\/li>\n<li><strong>Circuit vs. Protein:<\/strong> While current treatments try to clear out protein plaques, this approach focuses on fixing the <strong>neuronal circuits<\/strong> that have already become dysfunctional.<\/li>\n<li><strong>Repurposed Potential:<\/strong> Because Levodopa is already widely used for Parkinson\u2019s, this discovery opens an immediate path for clinical trials to see if it can slow or reverse early memory loss in human Alzheimer\u2019s patients.<\/li>\n<\/ul>\n<p><strong>Source: <\/strong>UC Irvine<\/p>\n<p>Why do memories fade in Alzheimer\u2019s disease \u2013 and can they be restored?<\/p>\n<p><strong>University of California, Irvine\u00a0researchers have uncovered a key mechanism underlying memory loss, showing for the first time that dopamine dysfunction in the entorhinal cortex, a critical memory-related brain region, contributes directly to impaired memory formation.<\/strong><\/p>\n<p>The study, published today in\u00a0Nature Neuroscience, identifies a previously unrecognized role for dopamine in Alzheimer\u2019s-related cognitive decline and points to potential therapeutic strategies using existing drugs such as Levodopa.<\/p>\n<p>  <img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/04\/dopamine-alzhimrs-memory-neuroscience.jpg\" alt=\"This shows a brain.\"  \/> Dopamine dysfunction plays a central role in memory impairment, offering a new path for dopamine-based therapies. Credit: Neuroscience News<\/p>\n<p>Memory allows us to connect experiences \u2013 linking a smell to a place or a sound to an event. While research has established that memory formation depends on the medial temporal lobe, often referred to as the brain\u2019s \u201cmemory center,\u201d the precise neural mechanisms that break down in Alzheimer\u2019s disease have remained unclear.<\/p>\n<p>Researchers led by\u00a0Kei Igarashi, Chancellor\u2019s Fellow and associate professor of anatomy and neurobiology at the UC Irvine School of Medicine, focused on the entorhinal cortex, a key gateway to the hippocampus that plays a central role in memory.<\/p>\n<p>In earlier\u00a0published\u00a0work, the team discovered that dopamine is essential for memory formation in this region. In the present study, they investigated whether disruption of this dopamine system contributes to memory impairment in Alzheimer\u2019s disease.<\/p>\n<p>Using a mouse model of Alzheimer\u2019s disease, the researchers found that dopamine levels in the entorhinal cortex were reduced to less than one-fifth of normal levels, and neurons no longer responded appropriately to stimuli that should be learned.<\/p>\n<p>To determine whether restoring dopamine could rescue memory function, the team increased dopamine levels in the entorhinal cortex using optogenetic techniques. This intervention restored the mice\u2019s ability to form memories. Importantly, administration of Levodopa \u2013 a drug widely used to treat Parkinson\u2019s disease \u2013 also normalized neural activity and improved memory performance.<\/p>\n<p>\u201cWe did not initially expect dopamine to be affected in Alzheimer\u2019s disease,\u201d Igarashi said. \u201cHowever, as the evidence accumulated, it became clear that dopamine dysfunction plays a central role in memory impairment.\u201d<\/p>\n<p>Alzheimer\u2019s disease affects tens of millions of people worldwide, and effective treatments remain limited. Current approaches have largely focused on removing toxic proteins such as amyloid-beta and tau from the brain, but these strategies often fail to restore memory once neuronal dysfunction has occurred.<\/p>\n<p>This discovery provides an important new piece in understanding how memory circuits break down in Alzheimer\u2019s disease and lays the groundwork for developing dopamine-based therapies. As associative memory declines early in the disease, targeting its underlying neural mechanisms may offer a promising path toward slowing cognitive decline.<\/p>\n<p>The research team also included Tatsuki Nakagawa, Jiayun L. Xie, Kiwon Park, Kai Cao, Marjan Savadkohighodjanaki, Yutian J. Zhang, Heechul Jun, Ayana Ichii, Jason Y. Lee, Shogo Soma, Yasmeen K. Medhat, at UC Irvine Department of Anatomy &amp; Neurobiology; and Takaomi C. Saido, RIKEN Center for Brain Science, Japan.<\/p>\n<p><strong>Funding: <\/strong>This work was supported by NIH R01 grants from the National Institutes of Health (R01MH121736, R01AG063864, R01AG066806, R01AG086441, R01MH137156, RF1AG091584), a BrightFocus Foundation Research Grant (A2019380S), an Alzheimer\u2019s Association Research Grant (AARG-17-532932), a Brain Research Foundation Grant (BRFSG-2017-04), a New Vision Research Award (CCAD201902), and a PRESTO grant from the Japan Science and Technology Agency (JPMJPR2481) to K.M.I. T.N. was supported by an Alzheimer\u2019s Association Research Fellowship (AARF-22-923955) and a BrightFocus Foundation Fellowship Grant (A2022018F).<\/p>\n<p>Key Questions Answered:<strong class=\"schema-faq-question\">Q: I thought dopamine was just about \u201cpleasure.\u201d What does it have to do with memory?<\/strong><\/p>\n<p class=\"schema-faq-answer\"><strong>A:<\/strong> While dopamine is famous for reward, it also acts as a \u201csave button\u201d in the brain\u2019s memory centers. Without enough dopamine in the entorhinal cortex, your brain can\u2019t \u201cstamp\u201d a new experience into your long-term memory, which is why events seem to vanish in Alzheimer\u2019s.<\/p>\n<p><strong class=\"schema-faq-question\">Q: Could Parkinson\u2019s medication be the \u201cmissing link\u201d for Alzheimer\u2019s?<\/strong><\/p>\n<p class=\"schema-faq-answer\"><strong>A:<\/strong> It\u2019s a very promising possibility. This study showed that <strong>Levodopa<\/strong> normalized neural activity and improved memory performance. Since the drug is already safety-tested and available, it could theoretically be fast-tracked for Alzheimer\u2019s research.<\/p>\n<p><strong class=\"schema-faq-question\">Q: Does this mean amyloid and tau don\u2019t matter?<\/strong><\/p>\n<p class=\"schema-faq-answer\"><strong>A:<\/strong> They still matter, but they might be the \u201carsonists\u201d that started the fire. Even after you put out the fire (remove the proteins), the \u201chouse\u201d (the dopamine circuit) is still damaged. This research suggests we need to repair the circuits to actually get the memory back.<\/p>\n<p>Editorial Notes:<\/p>\n<ul style=\"background-color:#ffffe8\" class=\"wp-block-list has-background\">\n<li>This article was edited by a Neuroscience News editor.<\/li>\n<li>Journal paper reviewed in full.<\/li>\n<li>Additional context added by our staff.<\/li>\n<\/ul>\n<p>About this Alzheimer\u2019s disease research news<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Author:\u00a0<\/strong><a href=\"https:\/\/www.utoronto.ca\/news\/authors-reporters\/don-campbell\" target=\"_blank\" rel=\"noreferrer noopener nofollow\"><a href=\"http:\/\/neurosciencenews.com\/cdn-cgi\/l\/email-protection#78150d0a0810011b17380d1b11561d1c0d\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Carly Murphy<\/a><br \/><strong>Source:\u00a0<\/strong><a href=\"https:\/\/uci.edu\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">UC Irvine<\/a><br \/><strong>Contact:\u00a0<\/strong>Carly Murphy \u2013 UC Irvine<br \/><strong>Image:\u00a0<\/strong>The image is credited to Neuroscience News<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Original Research:\u00a0<\/strong>Open access.<br \/>\u201c<a href=\"https:\/\/dx.doi.org\/10.1038\/s41593-026-02260-w\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Early dopamine disruption in the entorhinal cortex of a knock-in model of Alzheimer\u2019s disease<\/a>\u201d by Tatsuki Nakagawa,\u00a0Jiayun L. Xie,\u00a0Kiwon Park,\u00a0Kai Cao,\u00a0Marjan Savadkohighodjanaki,\u00a0Yutian J. Zhang,\u00a0Heechul Jun,\u00a0Ayana Ichii,\u00a0Jason Y. Lee,\u00a0Shogo Soma,\u00a0Yasmeen K. Medhat,\u00a0Takaomi C. Saido\u00a0&amp;\u00a0Kei M. Igarashi.\u00a0Nature Neuroscience<br \/><strong>DOI:10.1038\/s41593-026-02260-w<\/strong><\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p><strong>Early dopamine disruption in the entorhinal cortex of a knock-in model of Alzheimer\u2019s disease<\/strong><\/p>\n<p>The entorhinal cortex is a critical brain area for memory formation, while also the region exhibiting the earliest histological and functional alterations in Alzheimer\u2019s disease (AD).<\/p>\n<p>The entorhinal cortex therefore has been long hypothesized as one of the originating brain areas of AD pathophysiology, although circuit mechanisms causing its selective vulnerability remain poorly understood.<\/p>\n<p> Here we show that dopamine neurons projecting their axons to the lateral entorhinal cortex (LEC), critical for memory formation in healthy brains, become dysfunctional from the early pathological stage and cause associative memory impairments in amyloid precursor protein knock-in mice.<\/p>\n<p>Dopamine dysfunction led to the disruption of associative memory encoding of LEC layer 2\/3. Optogenetic reactivation of LEC dopamine fibers rescued associative learning behavior.\u00a0L-DOPA treatment restored memory encoding of LEC neurons and associative memory of amyloid precursor protein knock-in mice.<\/p>\n<p>These results suggest early dysfunction of LEC-projecting dopamine neurons underlie memory impairment in AD from early stages, pointing to a need for clinical investigation of LEC dopamine in patients with AD.<\/p>\n","protected":false},"excerpt":{"rendered":"Summary: For decades, Alzheimer\u2019s research has focused almost exclusively on toxic proteins like amyloid-beta and tau. However, a&hellip;\n","protected":false},"author":3,"featured_media":748990,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[11],"tags":[10263,14909,308390,210,45480,3810,912,831,80519,67,132,68],"class_list":["post-748989","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-alzheimers-disease","tag-dopamine","tag-entorhinal-cortex","tag-health","tag-levodopa","tag-memory","tag-neurology","tag-neuroscience","tag-uc-irvine","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116457678337271597","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/748989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=748989"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/748989\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/748990"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=748989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=748989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=748989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}